An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.108205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Christoph Wittich und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry and Molecular Biology II, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, German…. Hauptthemen laut MEDLINE: Palivizumab, Signal Transduction, Immunoglobulin G, Cytokine Receptor gp130. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Recently, we phenocopied interleukin (IL-)6 signaling using the dimerized single-chain variable fragment (scFv) derived from the respiratory syncytial virus IgG1-antibody palivizumab (PscFvLHFc) to activate a palivizumab antiidiotypic nanobody (AIPVHH)-gp130 receptor fusion protein. Palivizumab was unable to activate STAT3 signaling, so we aimed to create a similar ligand capable of triggering this pathway. Here, we created three variants of the ligand called PscFvLH0Fc, PscFvLH4Fc and PscFvLH8Fc by shortening the spacer region connecting PscFvLH and Fc from 23 amino acids in PscFvLHFc to 0 amino acids or expanding it by rigid linkers of four or eight alpha helical loops, respectively. The rigid-linker ligands had completely altered cellular activation patterns via AIPVHHgp130 fusion proteins. Deleting the extracellular stalk region between transmembrane and AIPVHH in the synthetic receptors AIP2VHHgp130Δstalk and AIP3VHHgp130Δstalk to increase rigidity and enhanced the biological activity of the short spacer PscFvFc ligands. Since scFv constructs are less stable than antibodies and have not been Food and Drug Administration approved, we looked for different antibody backbones. Transferring palivizumab's variable region to a more rigid and hence more agonistic IgG2 backbone (PIgG2) maintained affinity while improving agonistic properties activating cells expressing AIP2VHHgp130Δstalk and AIP3VHHgp130Δstalk but not their full-length counterparts. Furthermore, we engineered a tetravalent palivizumab variant (PscFvPIgG2) capable of inducing higher-order receptor clustering, activating Fas-induced apoptosis. In summary, we engineered a fully-synthetic cytokine/cytokine receptor pair based on the IgG2-variant of palivizumab and the AIPVHHgp130Δstalk variants opening avenues for therapeutic applications using nonphysiological targets in immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biochemistry and Molecular Biology II, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
- Institue of Molecular Medicine II, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
- Institute of Biochemistry and Molecular Biology II, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany. Electronic address: jscheller@uni-duesseldorf.de.
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Wittich, C., Ettich, J., Hertell, M., Ghosh Roy, B., Xu, H. C., Floss, D. M., Lang, P. A., & Scheller, J. (2025). An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.108205
Vancouver
Wittich C, Ettich J, Hertell M, Ghosh Roy B, Xu HC, Floss DM, et al. An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.108205
BibTeX
@article{Wittich2025,
author = {Wittich, Christoph and Ettich, Julia and Hertell, Marcel and Ghosh Roy, Biswadeep and Xu, Haifeng C and Floss, Doreen M and Lang, Philipp A and Scheller, Jürgen},
title = {An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.108205}
}
EUVIMED